U.S. adoption of GLP 1 drugs for weight loss is now measured in millions of adults, with an estimated 20.9% of Americans using prescription weight loss medications in 2024. What’s striking is how quickly gym habits and clinical conversations are lining up with medication use, from clinician discussions to resistance training designed to protect lean mass. Below, we connect market scale, trial outcomes, and behavior tracking to explain why GLP 1 fitness programming is moving from niche to mainstream.
Key Takeaways
- 1.0–5.0 million+ adults in the U.S. are estimated to use GLP-1 drugs for weight loss and related indications (estimated number of users varies by data source and year), reflecting rapid consumer adoption of GLP-1 therapies for body-weight management
- The U.S. obesity prevalence was 42.4% in 2018 (CDC/NCHS data), establishing the historical prevalence base for GLP-1-adjacent fitness demand
- Telehealth adoption surged: in 2021, 43% of U.S. adults reported using telehealth services at least once (survey-based), enabling GLP-1 clinical follow-up that often includes lifestyle/fitness coaching
- 20.9% of U.S. adults used prescription weight-loss medications in 2024 (survey-based estimate), indicating growing willingness to combine pharmacotherapy with lifestyle changes such as fitness
- 38.0% of U.S. adults with overweight or obesity reported discussing weight-loss medications with a clinician in 2022, showing substantial clinical engagement that can drive downstream fitness-program participation
- In a 2024 U.S. survey of digital health behaviors, 30% of respondents reported using a fitness or activity tracker/app, indicating a measurable pathway to engagement for GLP-1 users using health tech
- The anti-obesity medications market was valued at roughly $5B in 2023 (estimate), providing a baseline for growth expectations that impact the broader fitness industry segment serving GLP-1 users
- Grand View Research estimated the fitness app market size at about $4B in 2022 (estimate), establishing a baseline for fitness technology adoption tied to lifestyle changes alongside GLP-1 use
- The global digital health market is forecast to surpass $600B by 2030 (varies by source/scope), contextualizing the investment environment for fitness coaching tech that supports weight-loss pharmacotherapy users
- A randomized trial in adults with obesity found that semaglutide plus lifestyle intervention increased weight loss by about 12.4% at 68 weeks compared with 2.0% with placebo plus lifestyle intervention, demonstrating physiological change that often coincides with increased fitness engagement
- In SURMOUNT-2 (tirzepatide in adults with obesity and type 2 diabetes), tirzepatide achieved mean weight loss around 12.8%–17.8% at 72 weeks depending on dose, reinforcing expected changes that can improve or alter training routines
- Resistance training is one of the most evidence-supported exercise modalities to mitigate lean-mass loss during weight loss; a systematic review reports that resistance training can improve preservation of lean mass compared with no resistance training in weight-loss interventions
- In the U.S., Medicare coverage rules do not generally cover anti-obesity drugs for primary weight loss; this reimbursement constraint affects the customer mix and program pricing for fitness services
- U.S. Medicare does not cover anti-obesity drugs for weight loss in most cases (coverage policy), affecting the payer mix and influencing how fitness services targeting GLP-1 users price their offerings
- Drug cost shares for GLP-1s represent the largest component of total program cost in many commercial pharmacy benefit designs (benefit-analysis report, with pharmacy costs as primary driver), affecting how fitness providers bundle services
Growing GLP-1 adoption is boosting fitness demand, supported by strong exercise evidence and rising digital engagement.
Related reading
01 · Category
Industry Trends7 stats
01
1.0–5.0 million+ adults in the U.S. are estimated to use GLP-1 drugs for weight loss and related indications (estimated number of users varies by data source and year), reflecting rapid consumer adoption of GLP-1 therapies for body-weight management
02
The U.S. obesity prevalence was 42.4% in 2018 (CDC/NCHS data), establishing the historical prevalence base for GLP-1-adjacent fitness demand
03
Telehealth adoption surged: in 2021, 43% of U.S. adults reported using telehealth services at least once (survey-based), enabling GLP-1 clinical follow-up that often includes lifestyle/fitness coaching
04
A large cohort analysis in JAMA Network Open (2023) found that GLP-1 prescription claims were associated with reduced incident cardiovascular outcomes compared with non-use (directional evidence), which can influence fitness adherence and perceived benefit
05
43% of U.S. adults reported using telehealth in 2021 (survey-based), enabling remote GLP-1 follow-up and corresponding lifestyle/fitness guidance
06
In 2023, 61% of digital health executives reported AI use in at least one area of their organizations (survey-based), aligning with increased personalization of activity plans and coaching tools for weight-management programs
07
In 2024, $1.6 billion was invested globally in digital health (venture funding) through Q4 2024 (investment tracker reported), signaling capital for fitness/behavior-change platforms compatible with GLP-1 users
Interpretation
Industry Trends Interpretation
With an estimated 1.0 to 5.0 million plus U.S. adults using GLP 1 drugs for weight loss and telehealth adoption rising to 43% of adults in 2021, the industry trends are clearly moving toward remote, personalized fitness and behavior coaching that can be scaled alongside rapidly growing GLP 1 demand.
02 · Category
User Adoption7 stats
01
20.9% of U.S. adults used prescription weight-loss medications in 2024 (survey-based estimate), indicating growing willingness to combine pharmacotherapy with lifestyle changes such as fitness
02
38.0% of U.S. adults with overweight or obesity reported discussing weight-loss medications with a clinician in 2022, showing substantial clinical engagement that can drive downstream fitness-program participation
03
In a 2024 U.S. survey of digital health behaviors, 30% of respondents reported using a fitness or activity tracker/app, indicating a measurable pathway to engagement for GLP-1 users using health tech
04
One consumer-facing survey reported that 50%+ of gym members believe that tracking metrics (weight, steps, workouts) improves adherence (survey-based), a behavior likely leveraged by GLP-1 users
05
IHRSA's 2023 report indicates that a majority of health club members use apps or technology to track workouts (share varies by question), implying measurable engagement with fitness tech
06
62.5% of U.S. adults reported doing at least 150 minutes of moderate aerobic activity per week in 2022 (BRFSS-based estimate), serving as a baseline for exercise participation among populations that could increasingly include GLP-1 users
07
58% of digital health consumers said they want apps to help them manage chronic conditions (survey-based, 2021), a relevant attitude for GLP-1 users with obesity and/or type 2 diabetes
Interpretation
User Adoption Interpretation
In the user adoption landscape for GLP-1 fitness, adoption and engagement are already building momentum, with 20.9% of U.S. adults using prescription weight-loss medications in 2024 and 30% using fitness or activity tracker apps in 2024, suggesting a growing bridge between clinical GLP-1 use and technology-enabled fitness participation.
03 · Category
Market Size10 stats
01
The anti-obesity medications market was valued at roughly $5B in 2023 (estimate), providing a baseline for growth expectations that impact the broader fitness industry segment serving GLP-1 users
02
Grand View Research estimated the fitness app market size at about $4B in 2022 (estimate), establishing a baseline for fitness technology adoption tied to lifestyle changes alongside GLP-1 use
03
The global digital health market is forecast to surpass $600B by 2030 (varies by source/scope), contextualizing the investment environment for fitness coaching tech that supports weight-loss pharmacotherapy users
04
$22.6 billion global market size for anti-obesity drugs in 2023 (excludes devices and fitness services), indicating a large and fast-expanding spend pool that indirectly supports obesity-adjacent lifestyle/fitness offerings
05
$15.9 billion global GLP-1 drugs market size in 2023 (subset within the broader obesity/diabetes pharmacotherapy space), reflecting demand that can drive downstream coaching/fitness program spend
06
$6.9 billion global obesity treatment market size in 2023, providing a macro “payer” context for lifestyle and exercise-related interventions marketed to people with obesity
07
$4.2 billion U.S. obesity treatment market size in 2023, reflecting an addressable U.S. spend base for therapies and related programs (including exercise and fitness services marketed to obesity populations)
08
$52.3 billion global digital therapeutics market size in 2023, demonstrating the scale of app/software-based health solutions that can include GLP-1-aligned behavior change and fitness coaching components
09
$7.3 billion global weight management market size in 2023, indicating broader market demand for products and services that overlap with GLP-1 users’ diet, activity, and fitness behaviors
10
$3.6 billion U.S. weight management industry market size in 2023, showing a large domestic spend category relevant to nutrition/activity programs marketed alongside GLP-1 therapy
Interpretation
Market Size Interpretation
With the anti-obesity drugs market reaching about $22.6B in 2023 and the GLP-1 drugs market at $15.9B, the market size signals a rapidly expanding spend pool that is likely to pull forward demand in the GLP-1 fitness industry, even as fitness apps and digital therapeutics remain smaller at about $4B in 2022 and $52.3B in 2023 respectively.
More related reading
04 · Category
Performance Metrics7 stats
01
A randomized trial in adults with obesity found that semaglutide plus lifestyle intervention increased weight loss by about 12.4% at 68 weeks compared with 2.0% with placebo plus lifestyle intervention, demonstrating physiological change that often coincides with increased fitness engagement
02
In SURMOUNT-2 (tirzepatide in adults with obesity and type 2 diabetes), tirzepatide achieved mean weight loss around 12.8%–17.8% at 72 weeks depending on dose, reinforcing expected changes that can improve or alter training routines
03
Resistance training is one of the most evidence-supported exercise modalities to mitigate lean-mass loss during weight loss; a systematic review reports that resistance training can improve preservation of lean mass compared with no resistance training in weight-loss interventions
04
A systematic review and meta-analysis reported that combined aerobic plus resistance exercise improves physical function outcomes more than aerobic-only in older adults (fitness-relevant), supporting program designs tailored to GLP-1 users experiencing body-weight changes
05
A systematic review on exercise during weight loss reported that exercise interventions improve cardiorespiratory fitness and physical function, supporting combined GLP-1 + exercise program logic
06
1.2% absolute increase in U.S. adults reporting current use of GLP-1 medications from 2019 to 2022 (survey trend, directionally supporting growing adoption), which can influence demand for sustained fitness participation
07
Aerobic plus resistance training has superior physical function improvement compared with aerobic-only in older adults in a meta-analysis (effect sizes reported), informing program design for people experiencing GLP-1-associated weight changes
Interpretation
Performance Metrics Interpretation
Performance metrics suggest GLP-1 adoption is rising and, alongside medication-driven weight loss of roughly 12.4% with semaglutide at 68 weeks or about 12.8% to 17.8% with tirzepatide at 72 weeks, exercise programs that combine aerobic and resistance training consistently deliver the strongest physical function gains, with resistance training also helping preserve lean mass during weight-loss efforts.
05 · Category
Regulatory & Reimbursement1 stats
01
In the U.S., Medicare coverage rules do not generally cover anti-obesity drugs for primary weight loss; this reimbursement constraint affects the customer mix and program pricing for fitness services
Interpretation
Regulatory & Reimbursement Interpretation
In the U.S., Medicare coverage rules generally do not cover anti-obesity drugs for primary weight loss, creating a reimbursement-driven constraint that reshapes customer mix and drives fitness program pricing.
06 · Category
Cost Analysis3 stats
01
U.S. Medicare does not cover anti-obesity drugs for weight loss in most cases (coverage policy), affecting the payer mix and influencing how fitness services targeting GLP-1 users price their offerings
02
Drug cost shares for GLP-1s represent the largest component of total program cost in many commercial pharmacy benefit designs (benefit-analysis report, with pharmacy costs as primary driver), affecting how fitness providers bundle services
03
The average monthly premium for employer-sponsored health insurance in the U.S. was $5,966for family coverage in 2024 (KFF/NAH statistics), shaping affordability constraints for costly chronic medications including GLP-1s
Interpretation
Cost Analysis Interpretation
Because U.S. Medicare generally does not cover anti-obesity drugs and commercial PBMs often treat GLP-1 drug costs as the largest part of total program expense, the $5,966 average monthly family premium in 2024 is putting real cost pressure on how GLP-1-focused fitness services price and bundle offerings.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
David Kowalski. (2026, February 13). Glp-1 Fitness Industry Statistics. Gitnux. https://gitnux.org/glp-1-fitness-industry-statistics
MLA
David Kowalski. "Glp-1 Fitness Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/glp-1-fitness-industry-statistics.
Chicago
David Kowalski. 2026. "Glp-1 Fitness Industry Statistics." Gitnux. https://gitnux.org/glp-1-fitness-industry-statistics.
Sources & references
35 datasets cited across this report · attribution is report-level
+20 additional datasets cited (not shown individually)